Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
1actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-23 | actual | When the study began enrolling |
| Primary completion | 2026-05-31 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-31 | actual | The whole study's end, after follow-up |
| First posted | 2023-05-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- SARS-CoV-2
- COVID-19
- Post-Acute COVID-19 Syndrome
Intervention
- Biological: Pfizer-BioNTech COVID-19 mRNA vaccine — also filed as Pfizer-BioNTech COVID-19 Vaccine
Primary outcomes
what the primary-completion date above is the date OFAim 1: Any PCC-related diagnosis not present before the COVID-19 diagnosis
measured 30-180 days after COVID-19 diagnosis
Aim 2: Number of patients with a COVID-19 vaccination
measured Date of vaccine authorization through the end of the corresponding respiratory season
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed